Jefferies Starts Antares Pharma (ATRS) at Buy; Sees Over 100% Upside
Get Alerts ATRS Hot Sheet
Price: $5.59 --0%
Rating Summary:
5 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 6
Rating Summary:
5 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 6
Join SI Premium – FREE
Jefferies initiates coverage on Antares Pharma (NASDAQ: ATRS) with a Buy rating and a price target of $5.00.
Analyst Anthony Petrone commented, "ATRS is at a growth inflection following the recent OTREXUP settlement and ahead of the VIBEX EpiPEN launch with Teva. Risk-reward favorable considering OTREXUP/EpiPEN cycles, pipeline potential, and discounted valuation."
For an analyst ratings summary and ratings history on Antares Pharma click here. For more ratings news on Antares Pharma click here.
Shares of Antares Pharma closed at $2.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Assa Abloy (ASSAB:SS) (ASAZY) PT Raised to SEK275 at Citi
- Meta Platforms Inc. (META) PT Lowered to $500 at Oppenheimer
- Impinj Inc (PI) PT Raised to $160 at Needham
Create E-mail Alert Related Categories
Analyst Comments, Hot New Coverage, New CoverageRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!